{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-06T03:30:11.839Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-06. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-06. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-06, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"EDIT\",\n  \"company\": \"Editas Medicine, Inc.\",\n  \"investigation_summary\": \"EDIT is a cash-burning pre-clinical gene editing company that has raised ~$117M in a May 2026 equity offering (55.5M shares + warrants) days before this investigation was triggered. The Form 4 cluster — the stated trigger — consisted entirely of pre-arranged tax-withholding sales by three insiders (CEO, CFO, CSO), not open-market purchases. There are no genuine insider open-market buys in any recent window. EDIT-401 for hyperlipidemia is on track to file an IND mid-2026 with early human proof-of-concept data expected year-end 2026 — a real catalyst — but the stock is now heavily diluted post-offering and sitting near its post-offering low ($2.71 from ~$3.08 offer price). The options flow shows strong call-bias (95.6% net directional), but at micro-cap scale this reflects speculative interest, not institutional conviction. No asymmetric long setup exists given heavy dilution and the distance between current price ($2.71) and analyst target mean ($5.78). This warrants income-only consideration.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"csp\",\n    \"strangle\"\n  ],\n  \"business_snapshot\": \"Editas Medicine is a Cambridge, MA-based pre-clinical gene editing company built on CRISPR/Cas9 technology licensed from the Broad Institute and Harvard. The company's strategic pivot (December 2024) abandoned the reni-cel ex vivo sickle cell/beta-thalassemia program to focus exclusively on in vivo gene editing via lipid nanoparticle delivery. Lead program EDIT-401 upregulates the LDLR gene non-coding regulatory sequences to reduce LDL-C, demonstrating ≥90% mean LDL-C reduction in NHPs with an IND filing targeted for mid-2026 and early human proof-of-concept by year-end 2026. The company also has a CD19 Allo CAR T collaboration with BMS (14 programs total) and receives fixed Vertex license fees ($5M–$40M/year through 2034, partially sold to DRI Healthcare). Revenue is minimal from collaborations; the business model requires continuous financing. EDIT completed a ~$117M net equity offering in May 2026 (55.56M shares at $2.25 + warrants exercisable at $3.50), heavily diluting existing shareholders and signaling near-term cash fear rather than strength.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 43868,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-05\",\n      \"recent_eps_surprise_pattern\": \"Q4 2025: -$0.06 actual vs -$0.21 est (+72% beat); Q1 2026: -$0.26 actual vs -$0.24 est (-7.6% miss). Mixed recent pattern.\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"EDIT-401 IND filing target mid-2026 for LDL-C reduction via LDLR upregulation; early human PoC data expected year-end 2026. Topline Phase I dose-finding data planned for 2027.\",\n          \"date_or_window\": \"Mid-2026 IND, Q4 2026 PoC, 2027 topline\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/edit-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"USPTO reaffirmed PTAB decision favoring Broad Institute in CRISPR/Cas9 interference (March 2026) — positive IP resolution for EDIT's core technology licensing.\",\n          \"date_or_window\": \"2026-03-27\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthare/articles/editas-medicine-announces-u-patent-110000752.html\"\n          ],\n          \"directional_bias\": \"ambiguous\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 2026 earnings expected ~August 5, 2026. Q1 2026 loss of $0.26/share vs est $-0.24 — slightly worse than expected.\",\n          \"date_or_window\": \"2026-08-05\",\n          \"source_urls\": [],\n          \"directional_bias\": \"ambiguous\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"Preclinical EDIT-401 data presented at EAS Congress (May 2026): ~90% LDL-C, Lp(a), and ApoB reduction in NHPs; ≥90% durable LDL-C lowering maintained through ~6 months in mouse models.\",\n          \"date_or_window\": \"2026-05-26\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-presents-edit-401-100100102.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": -2.89,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -1.87,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": null,\n      \"narrative\": \"EDIT is a pre-clinical biotech with no product revenue and significant quarterly cash burn (~$25M Q1 2026). Post-offering market cap is ~$415M against ~$240-250M pro-forma cash, implying only ~$165-175M enterprise value for pipeline risk. At $2.71 vs analyst mean target of $5.78, there is a theoretical gap — but this gap reflects genuine binary clinical risk around the mid-2026 IND filing and subsequent human data, not mispricing in the traditional sense. No P/E or EBITDA comparison is meaningful given negative earnings.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"C\"\n    },\n    \"technical\": {\n      \"above_50dma\": false,\n      \"above_200dma\": null,\n      \"rsi_14\": 44.4,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 2.71,\n    \"ytd_return_pct\": -23.01,\n    \"from_52w_high_pct\": -40.26\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-03-09\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/edit-20251231.htm\",\n      \"key_takeaways\": [\n        \"EDIT abandoned reni-cel program December 2024, took $40.8M restructuring charge; reduced workforce ~65% (~180 positions)\",\n        \"Lead in vivo candidate EDIT-401 targets LDL-C via LDLR upregulation — ≥90% LDL-C reduction demonstrated in NHPs with single dose\",\n        \"IND filing targeted mid-2026; early human PoC expected year-end 2026, Phase I topline 2027\",\n        \"Vertex non-exclusive Cas9 license: $50M upfront received Q4 2023; fixed/sales-based annual fees $5–$40M through 2034 partially sold to DRI Healthcare for $57M upfront in Oct 2024\",\n        \"Cash and equivalents at Dec 31, 2025: $146.6M; accumulated deficit $1.63B as of Dec 31, 2025\",\n        \"85 U.S. patents + 57 pending U.S. patent applications under Broad/Harvard Cas9 license — USPTO reaffirmed Broad decision March 2026\",\n        \"BMS collaboration extended to November 2026 with up to 14 programs; CD19 HD Allo CAR T in Phase I for autoimmune disease\",\n        \"At-market equity offerings raised $43.9M gross through ATM Facility (March 2025); ~$106M still available\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-05\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000045/edit-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 revenue: $2.8M (vs $4.7M Q1 2025); collaboration/BMS revenue declining\",\n        \"Q1 2026 R&D expenses: $17.6M (down from $26.6M Q1 2025) — reflects restructuring and workforce reduction\",\n        \"Cash burn in operating activities: -$23.1M for Q1 2026; cash and equivalents March 31, 2026: $123.6M\",\n        \"Accumulated deficit at March 31, 2026: $1.65B\",\n        \"Stockholders' equity collapsed to $4.4M (from $27.3M Dec 31, 2025) — concerning balance sheet deterioration\",\n        \"Q1 2026 net loss: -$24.98M; restructuring charges eliminated vs $40.85M in Q1 2025 after reni-cel discontinuation\",\n        \"Liability for sale of future revenues (DRI deal): $54.7M as of March 31, 2026 — off-balance-sheet debt equivalent\",\n        \"Outstanding stock options: 12.62M shares; unvested RSUs: 493K\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/tm2615565d3_8k.htm\",\n      \"key_takeaways\": [\n        \"55.56M shares + 55.56M warrants at $2.25/share (combined); net proceeds ~$117M after discounts and expenses\",\n        \"Warrants exercisable at $3.50/share; expire earlier of Phase 1 data announcement or 3 years from issuance\",\n        \"Exercise price of $3.50 is 48% above the offering price — meaningful warrant overhang on upside\",\n        \"Company stated cash runway now extends to 'second half of 2028' with proceeds + existing cash\",\n        \"This was a dilutive offering at distressed-adjacent pricing ($2.25 vs prior day close ~$3.08); confirms near-term capital urgency\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-07-17\",\n      \"2026-08-21\"\n    ],\n    \"iv_summary\": \"IV data unavailable in fetched output; however, with ~12-month runway post-offering and a binary catalyst (IND filing mid-2026), IV likely elevated relative to sector median for micro-cap biotech. Post-offering overhang may suppress near-term IV.\",\n    \"notable_skew_or_flow\": \"Options flow on July 17 expiry shows extreme call-bias: put/call ratio of 0.02, net directional bias $2,596 in calls (95.6% call notional). Top OI strikes: 5C at 1,309 contracts vs 2.5P at 268 and 2.5C at 100. This reflects speculative bullish positioning around the mid-2026 catalyst window but at micro-cap scale (~$265K in total call notional) is more retail-driven than institutional.\"\n  },\n  \"competitive_landscape\": \"EDIT competes with CRISPR Therapeutics (CRSP: $51.84, $5.1B market cap) which already has CASGEVY approved for SCD and TDT via ex vivo BCL11A editing — a fundamentally different approach and stage. Within in vivo gene editing for LDL-C reduction, EDIT's EDIT-401 targets LDLR upregulation vs. Verve Therapeutics (molecular brake) and other cardiometabolic CRISPR/Novartis approaches. EDIT's key differentiation is its non-coding functional upregulation strategy requiring only ~10–40% allele editing to achieve ≥90% LDL-C reduction. IP position secured via Broad Institute USPTO reaffirmation March 2026.\",\n  \"key_risks\": [\n    \"Binary IND/clinical catalyst risk: mid-2026 IND filing and subsequent human PoC data are binary events for a pre-clinical biotech\",\n    \"Heavy dilution overhang: May 2026 offering of 55.56M shares + 55.56M warrants at $3.50 exercise creates persistent supply overhang on any rally above that level\",\n    \"Severe balance sheet deterioration: stockholders' equity collapsed from $27.3M to $4.4M in Q1 2026; accumulated deficit $1.65B — going-concern risk if programs fail\",\n    \"Cash burn without revenue: no product revenue capability; ~$25M/quarter burn vs. only $123–240M cash on hand (post-offering)\",\n    \"Patent licensing dependency: EDIT's CRISPR technology licensed from Broad/Harvard with milestone payments, sublicense obligations, and retained rights that could limit exclusivity\",\n    \"BMS collaboration expiration risk: BMS agreement extends to November 2026; non-renewal would eliminate a key revenue source\",\n    \"High short interest (~9.79% of float) reflects market skepticism about the business model viability\"\n  ],\n  \"what_the_market_might_be_missing\": \"Nothing material — this is a well-covered, frequently-analyzed micro-cap biotech with transparent disclosure and recent financing at current prices. The Form 4 cluster that triggered investigation was entirely tax-withholding sales under pre-arranged 10b5-1 plans (not discretionary), meaning the pipeline's 'smart money' signal is neutral-to-negative. EDIT-401's strong NHP data (~90% LDL-C reduction) and mid-2026 IND target are already priced in at current levels; analyst mean target of $5.78 reflects this upside but requires successful clinical progression.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"accounting\",\n    \"going_concern\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"10-K FY2025 filed 2026-03-09\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/edit-20251231.htm\"\n    },\n    {\n      \"label\": \"10-Q Q1 2026 filed 2026-05-05\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000045/edit-20260331.htm\"\n    },\n    {\n      \"label\": \"Form 4 CEO sale (O'Neill, 06/03/2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000056/xslF345X06/wk-form4_1780691579.xml\"\n    },\n    {\n      \"label\": \"Form 4 CFO sale (Parison, 06/03/2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000057/xslF345X06/wk-form4_1780691609.xml\"\n    },\n    {\n      \"label\": \"Form 4 CSO sale (Burkly, 06/03/2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000055/xslF345X06/wk-form4_1780691552.xml\"\n    },\n    {\n      \"label\": \"8-K Offering pricing May 26, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/tm2615565d3_8k.htm\"\n    },\n    {\n      \"label\": \"EDIT Q1 2026 earnings/results press release\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-announces-first-quarter-110000665.html\"\n    },\n    {\n      \"label\": \"EDIT EDIT-401 preclinical data EAS Congress May 26, 2026\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/editas-medicine-presents-edit-401-100100102.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-06T03:30:39.002Z",
      "raw_content": "<think>The dossier is for EDIT (Editas Medicine, Inc.), a pre-clinical gene editing company.\nScoring inputs:\n- Smart Money: 0 pts. No insider purchases. Material insider selling > buying ($43,868). Penalty: -10 pts (but floor is 0).\n- Options Flow: 0 pts. Call bias but micro-cap, speculative. No IV data.\n- Catalyst: 10 pts for earnings within 90 days? Earnings is 2026-08-05 (within 90 days from 2026-06-06). But EPS surprise pattern is mixed (Q4 beat, Q1 miss). 8 pts for pending product launch/FDA? IND filing mid-2026, PoC year-end 2026. Let's give 8 pts.\n- Mispricing: 0 pts. Negative earnings, no meaningful P/E or EV/EBITDA. Narrative says no mispricing in traditional sense.\n- Quality: 0 pts. Negative earnings, cash burn, equity collapsed to $4.4M.\n- Technical: 0 pts. Below 50DMA, RSI 44.4.\n\nScore breakdown:\nSmart money: 0\nOptions flow: 0\nCatalyst: 8\nMispricing: 0\nQuality: 0\nTechnical: 0\nTotal: ~8.\n\nAnti-signal gates:\n- anti_signals_present: [\"dilution\", \"accounting\", \"going_concern\"]\n- \"Going-concern audit qualification\" -> skip.\n- \"Customer concentration > 30%\" -> not mentioned.\n- \"Convert/warrant overhang > 10%\" -> warrants at $3.50 on 55.56M shares, definitely >10%.\n- \"Accounting irregularities\" -> listed.\n- \"Avg daily volume < $5M\" -> likely micro-cap, but not explicitly stated.\n- The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nGoing concern is a hard gate. Also, the company is cash-burning, pre-clinical, with equity collapsing to $4.4M. It's a classic biotech moonshot with severe financial distress signals and heavy dilution.\n\nEdge check: \"What does this idea say that the market doesn't already know?\" The dossier says \"Nothing material — this is a well-covered, frequently-analyzed micro-cap biotech...\". No edge.\n\nVerdict: range_bound_or_income. But the financials are terrible. Equity $4.4M, accumulated deficit $1.65B. Cash burn $25M/qtr. Even with $117M offering, it's a dying company. Not a trade.\n\nDecision: Skip.\nScore: ~8.\nReason: Severe going-concern risk, collapsing equity ($4.4M), heavy dilution overhang, and no credible asymmetric setup or income structure viable given the financial distress and binary clinical risk. Anti-signal gates trigger a skip.\n\nLet's compute score carefully to be safe:\nA: 0\nB: 0\nC: 8 (catalyst)\nD: 0\nE: 0\nF: 0\nTotal: 8.\n\nOutput matches skip format.\nCheck date rules: current date 2026-06-06. No dates needed in skip output except maybe in reason if I cite them, but I'll keep it brief.\nAll good.\nProceed. \nStructure:\n{\n  \"skip\": true,\n  \"score\": 8,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 0\n  },\n  \"reason\": \"Anti-signal gates (going_concern, dilution, accounting) trigger an automatic skip. The company's equity collapsed to $4.4M with $1.65B accumulated deficit, making it financially distressed despite the recent offering. No credible trade structure survives the financial and binary clinical risk profile.\"\n}\nCheck constraints: \"ONLY ONE STRUCTURE TYPE.\" -> skip format doesn't need it.\n\"OUTPUT ONLY VALID JSON.\"\nDone. \nSelf-Correction/Refinement during thought: \nWait, the prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will articulate why it doesn't apply or just state it triggers skip. The prompt says \"skip unless you can articulate WHY it doesn't apply\". I'll just say it applies and thus skips.\nScore is definitely low. I'll output the skip JSON.\nAll constraints met.\nProceed. \nOutput matches exactly. \nFinal check of the prompt: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will state that the anti-signals are valid and trigger the skip.\nReady. \nOutput Generation. \n```json\n{\n  \"skip\": true,\n  \"score\": 8,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 0\n  },\n  \"reason\": \"Anti-signal gates (going_concern, dilution, accounting) are active and valid. EDIT's stockholders' equity collapsed to $4.4M with a $1.65B accumulated deficit, creating severe financial distress despite the recent offering. The dossier confirms no edge over the market, and the binary clinical risk combined with structural overhang precludes a viable long or income setup.\"\n}\n```\nMatches requirements. Proceeds. \nNote: I'll make sure the JSON is strictly valid and contains no markdown if possible, but the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\" I will output raw JSON.\nDone. \nProceeds. \n[Output Generation] -> *Self-Correction/Verification during generation prep*:\nThe prompt says: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will output raw JSON string.\nScore breakdown sums to 8.\nReason is concise.\nAll good. \nProceeds. \n[Output] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 8,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 0\n  },\n  \"reason\": \"Anti-signal gates (going_concern, dilution, accounting) are active and valid. EDIT's stockholders' equity collapsed to $4.4M with a $1.65B accumulated deficit, creating severe financial distress despite the recent offering. The dossier confirms no edge over the market, and the binary clinical risk combined with structural overhang precludes a viable long or income setup.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 8,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 0\n  },\n  \"reason\": \"Anti-signal gates (going_concern, dilution, accounting) are active and valid. EDIT's stockholders' equity collapsed to $4.4M with a $1.65B accumulated deficit, creating severe financial distress despite the recent offering. The dossier confirms no edge over the market, and the binary clinical risk combined with structural overhang precludes a viable long or income setup.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 8,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 0\n  },\n  \"reason\": \"Anti-signal gates (going_concern, dilution, accounting) are active and valid. EDIT's stockholders' equity collapsed to $4.4M with a $1.65B accumulated deficit, creating severe financial distress despite the recent offering. The dossier confirms no edge over the market, and the binary clinical risk combined with structural overhang precludes a viable long or income setup.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 27164,
  "stop_reason": "stop",
  "completed_at": "2026-06-06T03:30:39.003Z"
}